<DOC>
	<DOCNO>NCT02774512</DOCNO>
	<brief_summary>This monocentric prospective non randomize phase 0 clinical trial target patient colon cancer upfront surgery advise pluridisciplinary team .</brief_summary>
	<brief_title>Predictive Biomarkers Biological Activity Efficacy Nilotinib ZAK Target Non-metastatic Colon Cancer</brief_title>
	<detailed_description>This monocentric prospective non randomize phase 0 clinical trial target patient colon cancer upfront surgery advise pluridisciplinary team . The surgical management change delay . The patient see consultation one two surgeon . The patient receive information consent participate study . A specific colonoscopy perform order take biopsy biological study . According expression level ZAK-0 , patient include corresponding arm : ZAK-0 expressor ZAK-0 non-expressor . Then patient receives nilotinib orally dose 800 mg/day ( 400 mg twice day ) 7 day . The patient schedule surgery morning last take nilotinib ( 12 hour ) . When colectomy perform , surgeon collect different tumoral sample immediately deliver laboratory . There additional change clinical follow .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>1 . Written inform consent sign prior studyrelated procedure . 2 . Histological diagnosis colon cancer . 3 . Performance status ECOG 0 , 1 , 2 . 4 . Physical status score ASA 1 2 . 5 . Patient without metastasis . 6 . No previous anticancer treatment colon cancer . 7 . Age ≥ 18 . 8 . Preoperative imaging : thoraxabdominalpelvis CT scan within 2 month . 9 . Colonoscopy biopsy determine ZAK0 expression level . 10 . Scheduled begin treatment 7 day surgical procedure . 11 . Adequate end organ function define : 11.1. total bilirubin &lt; 1.5 x ULN,1 11.2 . SGOT SGPT &lt; 2.5 x ULN , 11.3. creatinine &lt; 1.5 x ULN , 11.4 . Serum amylase lipase ≤ 1.5 x ULN , 11.5 . Alkaline phosphatase ≤ 2.5 x ULN unless consider tumor relate . 12 . Female patient childbearing potential must negative serum pregnancy test within 7 day initiation study drug . Women childbearing potential must agree use adequate contraception , accord investigator 's instruction . Effective contraception must place : During treatment nilotinib Until 2 week end treatment . 13 . Patients must follow laboratory value ( ≥ LLN ( low limit normal ) correct within normal limit supplement prior first dose study medication ) : 13.1 . Potassium ≥ LLN , 13.2 . Magnesium ≥ LLN , 13.3 . Phosphorus , ≥ LLN , 13.4 . Total calcium ( correct serum albumin ) ≥ LLN . 14 . Patients French social security compliance French law relate biomedical research ( Article L.112111 French Public Health Code ) . 1 . Rectal tumor ( 15 cm anus ) 2 . Any metastasis . 3 . Performance status ECOG ≥ 3 . 4 . Physical status score ASA ≥ 3 . 5 . Impaired cardiac function include one following : 5.1 . LVEF &lt; 45 % institutional low limit normal range ( whichever high ) determine locally read echocardiogram . 5.2 . Inability determine QT interval ECG . 5.3 . Complete leave bundle branch block . 5.4 . Use ventricularpaced pacemaker . 5.5 . Congenital long QT syndrome know family history long QT syndrome . 5.6 . History presence clinically significant ventricular atrial tachyarrhythmias . 5.7 . Clinically significant rest bradycardia ( &lt; 50 beat per minute ) . 5.8 . QTc &gt; 450 msec average three serial baseline ECG ( use QTcF formula ) determine central reading . If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc . 5.9 . History clinically document myocardial infarction . 5.10 . History unstable angina ( last 12 month ) . 5.11 . Other clinically significant heart disease ( e.g . congestive heart failure uncontrolled hypertension ) . 6 . Severe uncontrolled medical condition ( i.e . uncontrolled diabetes , active uncontrolled infection ) . 7 . History significant congenital acquire bleed disorder unrelated cancer . 8 . Major surgery within 4 week prior Day 1 study recover prior surgery . 9 . History noncompliance medical regimen inability grant consent . 10 . Use therapeutic coumarin derivative ( i.e. , warfarin , acenocoumarol , phenprocoumon ) . 11 . Patients actively receive therapy strong CYP3A4 inhibitor ( e.g. , erythromycin , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , ritonavir , mibefradil ) treatment either discontinue switched different medication prior start study drug . 12 . Patients actively receive therapy strong CYP3A4 inducer ( e.g. , dexamthasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbitol , St. John 's Wort ) treatment either discontinue switched different medication prior start study drug . 13 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection , gastric bypass surgery ) . 14 . History acute pancreatitis within 1 year study entry past medical history chronic pancreatitis . 15 . Acute chronic liver , pancreatic severe renal disease consider unrelated disease . 16 . Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug . 17 . Patients : ( ) pregnant , ( b ) breast feeding , ( c ) childbearing potential without negative pregnancy test prior baseline ( ) female childbearing potential unwilling use contraceptive precaution throughout trial two week end treatment ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Contraindication nilotinib administration . 18 . Previous current malignancy colon cancer within last 5 year , exception adequately treat basal cell squamous cell carcinoma skin . 19 . Emergency surgery , include occlusion . 20 . Previous enrolment present study . 21 . Patient unable follow comply study procedure geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>